Summary
Insilico Medicine's co-CEO Alex Zhavoronkov is betting on China and AI to drive the next breakthrough in drug discovery, with their AI-discovered drug, rentosertib, entering Phase 3 trials for idiopathic pulmonary fibrosis and showing potential in reversing biological aging.